ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,819.50
1.03%
S&P ASX All Technology
3,075.80
-0.06%
Brent Oil
86.685
-0.26%
US Dollar vs AUD
1.48965
-0.04%
Bitcoin
58,976.58
-1.97%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Eupraxia Pharmaceuticals Inc (EPRX)

  7. Eupraxia Pharmaceuticals Inc (EPRX) News

EPRX

Eupraxia Pharmaceuticals (EPRX)

Eupraxia Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:EPRX
DateTimeSourceHeadlineSymbolCompany
04/07/202407:00PR Newswire (US)Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
04/07/202407:00PR Newswire (Canada)Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
07/06/202407:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
07/06/202407:00PR Newswire (US)Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of ShareholdersNASDAQ:EPRXEupraxia Pharmaceuticals Inc
07/06/202407:00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of ShareholdersNASDAQ:EPRXEupraxia Pharmaceuticals Inc
05/06/202421:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
05/06/202421:00PR Newswire (US)Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
05/06/202421:00PR Newswire (Canada)Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
24/05/202407:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
24/05/202407:00PR Newswire (US)Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisNASDAQ:EPRXEupraxia Pharmaceuticals Inc
24/05/202407:00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisNASDAQ:EPRXEupraxia Pharmaceuticals Inc
22/05/202421:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
22/05/202421:00PR Newswire (Canada)Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
22/05/202421:00PR Newswire (US)Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
22/05/202407:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
22/05/202407:00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisNASDAQ:EPRXEupraxia Pharmaceuticals Inc
22/05/202407:00PR Newswire (US)Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisNASDAQ:EPRXEupraxia Pharmaceuticals Inc
16/05/202402:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
14/05/202421:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
14/05/202421:00PR Newswire (US)Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
14/05/202421:00PR Newswire (Canada)Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
09/05/202407:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
09/05/202407:03PR Newswire (Canada)Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:EPRXEupraxia Pharmaceuticals Inc
09/05/202407:03PR Newswire (US)Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:EPRXEupraxia Pharmaceuticals Inc
02/05/202421:00PR Newswire (US)Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory BoardNASDAQ:EPRXEupraxia Pharmaceuticals Inc
02/05/202421:00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory BoardNASDAQ:EPRXEupraxia Pharmaceuticals Inc
11/04/202421:00PR Newswire (US)Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
11/04/202421:00PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
08/04/202421:00PR Newswire (US)Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor ConferenceNASDAQ:EPRXEupraxia Pharmaceuticals Inc
08/04/202421:00PR Newswire (Canada)Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor ConferenceNASDAQ:EPRXEupraxia Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:EPRX

Your Recent History

ASX
WDC
Westfield
ASX
XTO
S&P ASX 100
ASX
NAB
National Australia Bank
ASX
CSL
CSL
FX
GBPAUD
Sterling vs AUD
COIN
BTCUSD
Bitcoin
FTSE
UKX
FTSE 100
NYSE
MCD
McDonalds
ASX
ANZ
Australia And New Zealan...
NASDAQ
GOOGL
Alphabet
ASX
QBE
QBE Insurance
NYSE
MRK
Merck
ASX
XAO
Australian SE All Ordina...
NYSE
VZ
Verizon Communications
NYSE
KO
Coca Cola
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved